NASDAQ

SeaStar Medical Holding Corporation (ICU)

431 Thanks from members

SeaStar Medical Holding Corporation (ICU) displays a high-risk, micro-cap biotechnology profile characterized by expanding commercial adoption of its QUELIMMUNE therapy for pediatric AKI, rising clinical trial expenses, ongoing net losses, and micro-cap stock volatility, including a recent 1-for-10 reverse stock split.

Special Briefing

How to Live for 300 Years: The Longevity Sandbox

Explore plasma cleansing, somatic organ swaps, and BCI.

Explore →